Summary & Overview
HCPCS J9060: Cisplatin Injection, 10 mg
HCPCS Level II code J9060 denotes the injectable chemotherapeutic agent cisplatin, in a 10 mg powder or solution unit. As a commonly used antineoplastic medication across oncology settings, accurate coding of J9060 is essential for clinical documentation, drug inventory management, and consistent reimbursement practices nationwide. The code captures a single 10 mg unit of cisplatin regardless of preparation form.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a national perspective on how J9060 is applied across payers and outlines the clinical context for cisplatin use in infusion settings.
Readers will learn: benchmarks and typical site-of-service expectations for injectable chemotherapy, payer coverage considerations at a national level, and operational implications for billing and claims submission when J9060 is used. The report also highlights common documentation elements and areas where coding clarity affects claim processing. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9060 represents injection, cisplatin, powder or solution, 10 mg. This code indicates administration of the chemotherapeutic agent cisplatin in a 10 mg unit of powder or solution form.
Service Type: Chemotherapy drug administration (injectable antineoplastic agent)
Typical Site of Service: Hospital outpatient department, infusion center, or oncology clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with newly diagnosed stage IIIA non-small cell lung cancer presents to the oncology infusion suite for systemic chemotherapy. The oncology team prescribes cisplatin-based combination chemotherapy. The patient undergoes pre-infusion nursing assessment, laboratory review (renal function, electrolytes), and informed consent. On the scheduled day, pharmacy compounds J9060 (cisplatin) into an appropriate diluent and concentration. The patient is pre-medicated for nausea and given intravenous hydration per institutional protocol. A registered nurse administers J9060 via intravenous infusion over the recommended timeframe with continuous monitoring for infusion-related reactions, nephrotoxicity, ototoxicity, and extravasation. Post-infusion, the patient is observed for a short recovery period, discharged with antiemetic prescriptions and follow-up oncology clinic appointment to assess response and manage toxicities. Typical site of service: outpatient hospital infusion center or ambulatory infusion clinic. Service type: chemotherapy drug administration (oncology outpatient infusion).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient | When part of a single-use vial is discarded after preparation and that discarded amount must be reported. |